News

Targeted Oncology9h

Lifileucel Offers Promising Long-Term Efficacy in Advanced Melanoma

During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in ...
Targeted Oncology9h

Oncologists Weigh Pros and Cons of Dual Oral Therapy in CLL

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...
Targeted Oncology15h

Immunosuppressive Antibody Discontinued After Patient Death in Lymphoma Trial

Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting ...
Targeted Oncology14h

Onvansertib Shows Promising Early Efficacy in First-Line KRAS-Mutated mCRC

Cardiff Oncology reveals promising results for onvansertib in treating KRAS- or NRAS-mutated metastatic colorectal cancer, ...
Targeted Oncology13h

Durable Efficacy of Intravesical Mitomycin Confirmed in Phase 3 Trial for NMIBC

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology16h

FDA Grants Priority Review for Liso-Cel in Marginal Zone Lymphoma

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology18h

Current Evidence and Future Directions

An expert discusses the complexities of sequencing antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer, emphasizing the need for biomarker-driven treatment personalization and ...